1 citations
,
April 2012 in “Journal of the American Academy of Dermatology” Clofazimine effectively treated a rare skin condition with ash-gray patches.
December 2021 in “OPAL (Open@LaTrobe) (La Trobe University)” Montelukast is linked to increased risks of suicidal thoughts and depression.
68 citations
,
September 2003 in “British Journal of Dermatology” Shrinking skin cancer increases the chance of cancer in nearby lymph nodes.
December 2025 in “Cureus” Higher IL-17A and IL-23 levels are linked to alopecia areata severity and could help in tracking and treating the disease.
169 citations
,
September 2002 in “British journal of dermatology/British journal of dermatology, Supplement” ZD1839 (Iressa) causes skin and hair side effects, treatable with tretinoin cream and minocycline.
April 2017 in “Leukemia research” Tofacitinib helped most teenagers in the study regrow hair with mild side effects.
2 citations
,
October 2022 in “Current Dermatology Reports” People on immune-modifying skin disease treatments may have a weaker antibody response to COVID-19 vaccines but often improve after the second dose.
213 citations
,
June 2017 in “Rheumatology” The guidelines suggest a detailed approach to diagnosing and treating lupus, with a focus on regular check-ups, personalized medicine, and a range of drug options for different cases.
October 2022 in “The American journal of gastroenterology” Thymoma-associated multiorgan autoimmunity can cause liver damage and affects multiple organs, with limited treatment options and a generally poor prognosis.
July 2024 in “Journal of Investigative Dermatology” DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.
3 citations
,
May 2023 in “Clinical drug investigation” JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
January 2023 in “Faculty of 1000 Research Ltd” People with weakened immune systems, like those with SLE, are at higher risk for TB.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Oral Janus kinase inhibitors may be an effective treatment option for lichen planopilaris with some risk of increased cholesterol and liver enzyme levels.
Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.
6 citations
,
September 2021 in “Medical Journal of Cell Biology” Mesenchymal stem cells and their secretome may offer a safe and effective treatment for systemic lupus erythematosus.
1 citations
,
January 2015 in “Journal of Arthritis” Lupus pneumonitis can mimic tuberculosis and should be considered in diagnoses.
10 citations
,
March 2015 in “Journal of dermatology” The boy's severe skin disorder is caused by two new mutations in his TGM1 gene.
1 citations
,
September 2025 in “JAAD reviews.” Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.
September 2023 in “Journal of the American Academy of Dermatology” Topical tofacitinib helped a man with severe scalp condition after other treatments failed.
December 2023 in “Journal of Multiple Sclerosis and Neuroimmunology” Teriflunomide can cause hair thinning.
IL-18 signaling helps mature Tregs move into the thymus.
July 2025 in “Journal of the European Academy of Dermatology and Venereology”
January 2024 in “International Journal of Dermatology” Targeting Interleukin-13 could help treat alopecia areata linked with atopic dermatitis.
May 2025 in “The Journal of Rheumatology” Trans-esophageal echocardiography is crucial for accurately diagnosing heart issues in lupus patients.
January 2026 in “Frontiers in Public Health” Baricitinib and tofacitinib have different safety patterns in treating alopecia areata.
1 citations
,
January 2024 in “Dermatologic Therapy” Combining tacrolimus with excimer light is more effective for treating alopecia areata than using excimer light alone.
October 2023 in “International journal of rheumatic diseases” New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.
January 2026 in “Dermatology Reports” Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.
December 2025 in “International Journal of Innovative Technologies in Social Science” Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.
Tofacitinib helped a woman with total-body hair loss grow her hair back.